What is ImmVirX?
ImmVirX is at the forefront of immuno-oncology, developing a novel approach using proprietary bio-selected RNA viruses. These viruses are engineered to target specific receptor proteins that are highly expressed on various cancer cell types. Upon selective entry, the viruses replicate within tumor cells, leading to their destruction. Furthermore, ImmVirX's technology is designed to induce beneficial changes within the tumor micro-environment, potentially enhancing the body's immune response against cancer. This innovative strategy positions ImmVirX as a key player in the development of next-generation cancer therapies.
How much funding has ImmVirX raised?
ImmVirX has raised a total of $47M across 2 funding rounds:
Other Financing Round
$22M
Series B
$25M
Other Financing Round (2021): $22M with participation from Hunter Medical Research Institute and University of Newcastle Australia
Series B (2023): $25M led by OneVentures and Acorn Capital Investment Fund
Key Investors in ImmVirX
Hunter Medical Research Institute
The Hunter Medical Research Institute (HMRI) is a leading Australian medical research institute focused on a broad spectrum of health challenges, including cancer research. Their involvement suggests a strong alignment with ImmVirX's therapeutic goals and a commitment to advancing innovative cancer treatments through scientific discovery.
University of Newcastle Australia
The University of Newcastle Australia is a world-class institution with a strong emphasis on research and innovation. Its participation in ImmVirX's funding highlights the university's commitment to translating cutting-edge scientific research into practical applications, particularly in the field of biotechnology and medicine.
OneVentures
OneVentures is a prominent venture capital firm that typically invests in high-growth technology and life science companies. Their backing of ImmVirX indicates a strategic focus on disruptive technologies with significant market potential in the healthcare sector.
What's next for ImmVirX?
The recent major strategic investment in ImmVirX signals a pivotal growth phase for the company. This capital infusion is expected to accelerate the development and potential commercialization of its immuno-oncology platform. Investors, including specialized venture capital firms and research institutions, are likely backing ImmVirX for its unique technological approach and its potential to address unmet needs in cancer treatment. The company is poised to leverage this financing to advance its clinical pipeline, expand its research and development capabilities, and forge strategic partnerships, further solidifying its position in the competitive biotech landscape.
See full ImmVirX company page
